Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L3 pseudogene 2 (RPL3P2) is a genetic element classified as a pseudogene. Unlike the functional ribosomal protein L3 gene (RPL3), which encodes a core component of the 60S ribosomal subunit and is essential for protein synthesis[8][7][5], RPL3P2 does not possess coding potential for a functional protein[3]. Pseudogenes such as RPL3P2 are typically remnants of evolutionarily duplicated genes that have lost their protein-coding ability due to mutations. There is no evidence to suggest that RPL3P2 serves as a therapeutic target, nor is there information to indicate involvement in disease mechanisms, drug interaction, or biomarker use[3][9]. It is most appropriately classified as a non-coding pseudogene rather than a receptor, enzyme, or other canonical target class. RPL3P2 does not represent a viable drug target, biomarker, or disease-related protein, and its inclusion in target selection lists likely represents an error or misunderstanding of its molecular status[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L3 pseudogene 2 (RPL3P2).